NCT05956977 2023-07-24
Neuro3DUS
University of Ulm
Phase NA Unknown
Clinical Trials
4 trialsNCT03189576 2023-05-26
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Tampere University Hospital
Phase NA Unknown
NCT05603156 2022-11-02
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT02185261 2018-06-07
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
Phase NA Unknown